GF Fund Management CO. LTD. Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

GF Fund Management CO. LTD. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 368,661 shares of the company's stock, valued at approximately $10,894,000. GF Fund Management CO. LTD. owned approximately 0.17% of Hims & Hers Health as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in HIMS. Private Advisor Group LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $312,000. Bank of New York Mellon Corp raised its position in shares of Hims & Hers Health by 128.7% during the 4th quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company's stock valued at $30,103,000 after acquiring an additional 700,500 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $876,000. Mutual of America Capital Management LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $700,000. Finally, US Bancorp DE raised its position in shares of Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after acquiring an additional 1,508 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Irene Becklund sold 8,485 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $506,978.75. Following the completion of the sale, the insider owned 712 shares in the company, valued at $42,542. This represents a 92.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 23,107 shares of the company's stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the sale, the chief financial officer owned 63,222 shares of the company's stock, valued at approximately $2,987,239.50. This trade represents a 26.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 692,006 shares of company stock valued at $34,857,872. 13.71% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HIMS has been the topic of several research reports. Truist Financial set a $45.00 price target on Hims & Hers Health in a research report on Tuesday, June 24th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Sunday, June 15th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $39.58.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $0.46 on Friday, hitting $47.92. The company's stock had a trading volume of 17,394,334 shares, compared to its average volume of 23,391,440. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The company has a market capitalization of $10.72 billion, a price-to-earnings ratio of 69.44, a price-to-earnings-growth ratio of 1.76 and a beta of 2.02. The stock's 50-day moving average is $52.23 and its two-hundred day moving average is $40.20.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The company's revenue was up 110.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.05 earnings per share. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.